Propanc Biopharma Inc (NASDAQ:PPCB) Short Interest Update

Posted by Francis Steltz on Aug 12th, 2026

Propanc Biopharma Inc (NASDAQ:PPCB – Get Free Report) saw a large decrease in short interest in July. As of July 31st, there was short interest totaling 20,152 shares, a decrease of 84.9% from the July 15th total of 133,524 shares. Based on an average daily trading volume, of 99,223 shares, the days-to-cover ratio is currently 0.2 days. Approximately 1.2% of the company’s stock are sold short.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Propanc Biopharma in a research report on Wednesday, July 29th. One analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company presently has a consensus rating of “Sell”.

Check Out Our Latest Report on Propanc Biopharma

Propanc Biopharma Stock Up 4.3%

PPCB traded up $0.05 on Wednesday, reaching $1.22. The company’s stock had a trading volume of 25,963 shares, compared to its average volume of 1,667,111. The company has a market capitalization of $2.78 million, a price-to-earnings ratio of -0.05 and a beta of 3.52. Propanc Biopharma has a fifty-two week low of $0.95 and a fifty-two week high of $260.00. The stock has a 50 day moving average of $1.51 and a two-hundred day moving average of $2.85.

Propanc Biopharma declared that its board has initiated a stock repurchase plan on Thursday, June 11th that authorizes the company to repurchase $5.00 million in shares. This repurchase authorization authorizes the company to reacquire up to 162.3% of its stock through open market purchases. Stock repurchase plans are usually a sign that the company’s board of directors believes its stock is undervalued.

Institutional Investors Weigh In On Propanc Biopharma

An institutional investor recently bought a new position in Propanc Biopharma stock. Virtu Financial LLC acquired a new stake in Propanc Biopharma Inc (NASDAQ:PPCB – Free Report) during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 41,677 shares of the company’s stock, valued at approximately $71,000. Virtu Financial LLC owned 0.33% of Propanc Biopharma as of its most recent filing with the Securities and Exchange Commission.

Propanc Biopharma Company Profile

(Get Free Report)

Propanc Biopharma Ltd is a clinical-stage biotechnology company focused on developing novel biologic drug candidates for the treatment of invasive and metastatic cancers. The company’s core technology centers on proprietary formulations of recombinant human proteolytic enzymes designed to degrade the dense extracellular matrix that surrounds solid tumors. By reducing stromal barriers, these candidates are intended to enhance the delivery and efficacy of co-administered chemotherapies, immunotherapies or other targeted agents.

The company’s lead program, known as PRP, comprises a combination of modified pancreatic proteases that have demonstrated promising preclinical activity in degrading tumor stroma and inhibiting tumor growth.